Discovery of Novel Trace Amine-Associated Receptor 5 (TAAR5) Antagonists Using a Deep Convolutional Neural Network.
AtomNet
BRET
antagonist
trace amine-associated receptor 5
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
14 Mar 2022
14 Mar 2022
Historique:
received:
05
02
2022
revised:
06
03
2022
accepted:
10
03
2022
entrez:
25
3
2022
pubmed:
26
3
2022
medline:
9
4
2022
Statut:
epublish
Résumé
Trace amine-associated receptor 5 (TAAR5) is a G protein-coupled receptor that belongs to the TAARs family (TAAR1-TAAR9). TAAR5 is expressed in the olfactory epithelium and is responsible for sensing 3-methylamine (TMA). However, recent studies showed that TAAR5 is also expressed in the limbic brain regions and is involved in the regulation of emotional behaviour and adult neurogenesis, suggesting that TAAR5 antagonism may represent a novel therapeutic strategy for anxiety and depression. We used the AtomNet
Identifiants
pubmed: 35328548
pii: ijms23063127
doi: 10.3390/ijms23063127
pmc: PMC8954676
pii:
doi:
Substances chimiques
Ligands
0
Receptors, G-Protein-Coupled
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Russian Science Foundation
ID : 19-75-30008
Références
Genes Brain Behav. 2007 Oct;6(7):628-39
pubmed: 17212650
Mol Pharmacol. 2001 Dec;60(6):1181-8
pubmed: 11723224
Neurosci Lett. 2019 Nov 1;712:134470
pubmed: 31476355
Front Mol Neurosci. 2020 Mar 05;13:18
pubmed: 32194374
Nat Rev Drug Discov. 2003 Mar;2(3):192-204
pubmed: 12612645
J Med Chem. 2020 Aug 27;63(16):8867-8875
pubmed: 32787146
Nat Rev Drug Discov. 2021 Oct;20(10):725-727
pubmed: 34522032
Nucleic Acids Res. 2018 Jul 2;46(W1):W296-W303
pubmed: 29788355
Sci Rep. 2021 Nov 29;11(1):23092
pubmed: 34845253
Front Endocrinol (Lausanne). 2012 Aug 29;3:105
pubmed: 22952466
Neuropharmacology. 2021 Jan;182:108373
pubmed: 33132188
N Engl J Med. 2020 Apr 16;382(16):1497-1506
pubmed: 32294346
Neuropharmacology. 2014 Jun;81:283-91
pubmed: 24565640
Front Pharmacol. 2018 Jun 21;9:645
pubmed: 29977204
J Med Chem. 2002 Jun 6;45(12):2615-23
pubmed: 12036371
J Pharmacol Exp Ther. 2008 Mar;324(3):948-56
pubmed: 18083911
Methods Mol Biol. 2013;964:107-22
pubmed: 23296781
Int J Mol Sci. 2021 Jun 25;22(13):
pubmed: 34202385
Neurosci Lett. 2018 Feb 14;666:144-147
pubmed: 29288046
Biochem Biophys Res Commun. 1998 Jan 26;242(3):575-8
pubmed: 9464258
Brain Res Bull. 2020 May;158:116-121
pubmed: 32151716
J Neurochem. 2004 Jul;90(2):257-71
pubmed: 15228583
Nature. 2021 Aug;596(7873):583-589
pubmed: 34265844
Nucleic Acids Res. 2022 Jan 7;50(D1):D439-D444
pubmed: 34791371
Neuropharmacology. 2015 Jun;93:308-13
pubmed: 25721394
Nature. 2006 Aug 10;442(7103):645-50
pubmed: 16878137
Eur Neuropsychopharmacol. 2015 Nov;25(11):2049-61
pubmed: 26372541
Mol Pharmacol. 2008 Sep;74(3):585-594
pubmed: 18524885
Nature. 2020 Jul;583(7818):862-866
pubmed: 32555462
Angew Chem Int Ed Engl. 2013 Jun 17;52(25):6366-78
pubmed: 23650015
Proc Natl Acad Sci U S A. 2011 May 17;108(20):8485-90
pubmed: 21525407
Cell Metab. 2019 Dec 3;30(6):1131-1140.e7
pubmed: 31564441
J Mol Graph Model. 1997 Dec;15(6):359-63, 389
pubmed: 9704298
Eur J Med Chem. 2017 Feb 15;127:781-792
pubmed: 27823885
Proc Natl Acad Sci U S A. 2001 Jul 31;98(16):8966-71
pubmed: 11459929
Mol Pharmacol. 2011 Sep;80(3):416-25
pubmed: 21670104
PLoS One. 2015 Feb 23;10(2):e0117774
pubmed: 25706283
Neurotox Res. 2018 Oct;34(3):442-451
pubmed: 29713997
Front Pharmacol. 2019 May 03;10:470
pubmed: 31130864
Pharmacol Res. 2016 Jan;103:206-14
pubmed: 26640076
Curr Biol. 2013 Jan 7;23(1):11-20
pubmed: 23177478
Pharmacol Rev. 2018 Jul;70(3):549-620
pubmed: 29941461
Curr Biol. 2020 Dec 7;30(23):4643-4653.e3
pubmed: 33035477
Int J Mol Sci. 2021 Aug 16;22(16):
pubmed: 34445502